TOday’s Movers: Ampliphi Biosciences (APHB) Stock Rating Reiterated by H.C. Wainwright; $6.0000 Target Price Indicates 450.46 % Potential

May 16, 2018 - By Ellis Scott

AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) Logo

Ampliphi Biosciences (APHB) Rating Reaffirmed

H.C. Wainwright now has a $6.0000 target price on the $17.95M market cap company or 450.46 % upside potential. In a research note revealed to clients on Wednesday, 16 May, Ampliphi Biosciences (APHB) shares have had their Buy Rating reconfirmed by stock analysts at H.C. Wainwright.

The stock decreased 7.92% or $0.09 during the last trading session, reaching $1.09. About 273,453 shares traded. AmpliPhi Biosciences Corporation (APHB) has declined 77.34% since May 17, 2017 and is downtrending. It has underperformed by 88.89% the S&P500.

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage technology. The company has market cap of $17.95 million. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. It currently has negative earnings. The firm has reported results from two Phase I clinical trials of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients, as well as evaluating the safety of AB-SA01 when administered topically to the intact skin of healthy adults.

AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.